SCHEMBL2615342

SCHEMBL2615342

OCCOCCN1CCN(C2=Nc3ccc(F)cc3Sc3ccccc32)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 3/20 0.80
ADRA2A P08913 2/20 0.80
LMNA P02545 1/20 0.80
CHRM2 P08172 1/20 0.80
CHRM4 P08173 1/20 0.80
CYP3A4 P08684 1/20 0.80
HTR1A P08908 1/20 0.80
CHRM5 P08912 1/20 0.80
CHRM1 P11229 1/20 0.80
ADRA2B P18089 1/20 0.80
ADRA2C P18825 1/20 0.80
CHRM3 P20309 1/20 0.80
DRD1 P21728 1/20 0.80
DRD4 P21917 1/20 0.80
HRH2 P25021 1/20 0.80
ADRA1D P25100 1/20 0.80
HTR2A P28223 1/20 0.80
HTR2C P28335 1/20 0.80
HTR7 P34969 1/20 0.80
ADRA1A P35348 1/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13284387 0.92 DRD2 (0.67) DRD2ADRA2ALMNACHRM2CHRM4
SCHEMBL13284556 0.90 DRD2 (0.80) DRD2ADRA2ALMNACHRM2CHRM4
SCHEMBL141875 0.89 ADRA2A (0.81) DRD2ADRA2ALMNACHRM2CHRM4
SCHEMBL29549271 0.89 ADRA2A (0.81) DRD2ADRA2ALMNACHRM2CHRM4
Quetiapine SCHEMBL7932 0.89 DRD2 (1.00) DRD2ADRA2ALMNACHRM2CHRM4
Quetiapine SCHEMBL4283801 0.89 DRD2 (1.00) DRD2ADRA2ALMNACHRM2CHRM4
Quetiapine SCHEMBL29360153 0.89 DRD2 (1.00) DRD2ADRA2ALMNACHRM2CHRM4
Quetiapine SCHEMBL4638768 0.89 DRD2 (1.00) DRD2ADRA2ALMNACHRM2CHRM4
Quetiapine SCHEMBL2537668 0.88 DRD2 (0.94) DRD2ADRA2ALMNACHRM2CHRM4
Quetiapine SCHEMBL396057 0.88 DRD2 (0.98) DRD2ADRA2ALMNACHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095217-A1 FLUORINE CONTAINING COMPOUNDS AND METHODS OF USE THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2012-04-19 US disclosed
US-20120095217-A1 FLUORINE CONTAINING COMPOUNDS AND METHODS OF USE THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2012-04-19 US disclosed
WO-2010081036-A2 FLUORINE CONTAINING COMPOUNDS AND METHODS OF USE THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095217-A1 FLUORINE CONTAINING COMPOUNDS AND METHODS OF USE THEREOF FLI1, CDC73, FOS DRD2 2857/4885ADRA2A 4623/4885LMNA 1375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.